Chiltern names Andrew Monaghan director, global pharmacovigilance
Global CRO Chiltern International has appointed Andrew Monaghan, Ph.D., director, global pharmacovigilance. Monaghan will lead the pharmacovigilance team and expand the company’s pharmacovigilance offering.
Monaghan has more than 30 years of experience in clinical R&D, most recently as global head of safety operations at Roche Products, U.K., where he led and managed 500 safety operations staff across seven locations globally.
He led the clinical development of two major products and managed several products through regulatory submission and approval. He has worked in the U.S. and France in regulatory affairs and was the global head of study management and data management groups.